CORD-19:ee0a7632371a08727d41e55aad7d621daeceef7d / 532095-532291 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T54298","span":{"begin":0,"end":196},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"In this study we investigate TP53 and LKB1/STK11 mutation co-occurrence with major subtypes of KRAS as potential biomarkers for efficacy of MEK inhibitors in NSCLC patients within our institution."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T310","span":{"begin":0,"end":196},"obj":"Sentence"}],"text":"In this study we investigate TP53 and LKB1/STK11 mutation co-occurrence with major subtypes of KRAS as potential biomarkers for efficacy of MEK inhibitors in NSCLC patients within our institution."}

{"project":"CORD-19-PD-HP","denotations":[{"id":"T1041","span":{"begin":158,"end":163},"obj":"Phenotype"}],"attributes":[{"id":"A1041","pred":"hp_id","subj":"T1041","obj":"http://purl.obolibrary.org/obo/HP_0030358"}],"text":"In this study we investigate TP53 and LKB1/STK11 mutation co-occurrence with major subtypes of KRAS as potential biomarkers for efficacy of MEK inhibitors in NSCLC patients within our institution."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T2559","span":{"begin":158,"end":163},"obj":"Disease"},{"id":"T2512","span":{"begin":158,"end":163},"obj":"Disease"}],"attributes":[{"id":"A2559","pred":"mondo_id","subj":"T2559","obj":"http://purl.obolibrary.org/obo/MONDO_0005233"},{"id":"A84752","pred":"mondo_id","subj":"T2512","obj":"http://purl.obolibrary.org/obo/MONDO_0005233"}],"text":"In this study we investigate TP53 and LKB1/STK11 mutation co-occurrence with major subtypes of KRAS as potential biomarkers for efficacy of MEK inhibitors in NSCLC patients within our institution."}